Lupin gains on launching generic Acticlate tablets in US

03 Nov 2017 Evaluate

Lupin is currently trading at Rs. 1069.50, up by 8.60 points or 0.76% from its previous closing of Rs. 1060.90 on the BSE.

The scrip opened at Rs. 1062.00 and has touched a high and low of Rs. 1070.35 and Rs. 1062.00 respectively. So far 6,677 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1572.25 on 06-Feb-2017 and a 52 week low of Rs. 920.00 on 21-Aug-2017.

Last one week high and low of the scrip stood at Rs. 1090.00 and Rs. 993.50 respectively. The current market cap of the company is Rs. 48,329.00 crore.

The promoters holding in the company stood at 46.80%, while Institutions and Non-Institutions held 40.05% and 13.14% respectively.

Lupin has launched Doxycycline Hyclate Tablets USP, 75 mg and 150 mg having received an approval from the United States Food and Drug Administration (USFDA) earlier. Lupin’s Doxycycline Hyclate Tablets USP, 75 mg and 150 mg are the AB rated generic equivalent of Aqua Pharmaceuticals, LLC’s Acticlate Tablets, 75 mg and 150 mg. They are indicated in the treatment of infections caused by various microorganisms and as an adjunctive therapy in severe acne.

Doxycycline Hyclate Tablets USP, 75 mg and 150 mg had annual sales of around USD 263 million in the US, as per IMS MAT June 2017.


Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.


Lupin Share Price

2071.35 -26.30 (-1.25%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×